Viridian Therapeutics, Inc./DE Reclassifications of Temporary to Permanent Equity
Viridian Therapeutics, Inc./DE (VRDN) reported Reclassifications of Temporary to Permanent Equity of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-14.
Discontinued › Shareholders' Equity
us-gaap:ReclassificationsOfTemporaryToPermanentEquity · last filed 2019-03-14
- Viridian Therapeutics, Inc./DE reclassifications of temporary to permanent equity for the quarter ending 2018-12-31 was $0.00.
- Viridian Therapeutics, Inc./DE reclassifications of temporary to permanent equity for the quarter ending 2018-09-30 was $0.00.
- Viridian Therapeutics, Inc./DE reclassifications of temporary to permanent equity for the quarter ending 2018-06-30 was $0.00.
- Viridian Therapeutics, Inc./DE reclassifications of temporary to permanent equity for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE reclassifications of temporary to permanent equity for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- Viridian Therapeutics, Inc./DE reclassifications of temporary to permanent equity for fiscal 2017 was $76.98M.
- Viridian Therapeutics, Inc./DE reclassifications of temporary to permanent equity for fiscal 2016 was $0.00.
| Period end | Reclassifications of Temporary to Permanent Equity 3 month | Reclassifications of Temporary to Permanent Equity 6 month | Reclassifications of Temporary to Permanent Equity 9 month | Reclassifications of Temporary to Permanent Equity 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $0.00 derived: sum of 2 quarters · filed 2019-03-14 | $0.00 derived: sum of 3 quarters · filed 2019-03-14 | $0.00 10-K · filed 2019-03-14 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | $0.00 derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $0.00 10-Q · filed 2018-08-08 | $0.00 derived: sum of 3 quarters · filed 2019-03-14 | $0.00 derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-09 | $0.00 derived: sum of 2 quarters · filed 2019-03-14 | $0.00 derived: sum of 3 quarters · filed 2019-03-14 | $0.00 derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $0.00 derived: sum of 2 quarters · filed 2019-03-14 | $0.00 derived: sum of 3 quarters · filed 2019-03-14 | $76.98M 10-K · filed 2019-03-14 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $76.98M 10-Q · filed 2018-11-07 | $76.98M derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $76.98M 10-Q · filed 2018-08-08 | $76.98M derived: sum of 3 quarters · filed 2018-08-08 | $76.98M derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-03-31 | $76.98M 10-Q · filed 2018-05-09 | $76.98M derived: sum of 2 quarters · filed 2018-05-09 | $76.98M derived: sum of 3 quarters · filed 2018-05-09 | $76.98M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $0.00 derived: sum of 2 quarters · filed 2018-03-15 | $0.00 derived: sum of 3 quarters · filed 2018-03-15 | $0.00 10-K · filed 2018-03-15 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $0.00 10-Q · filed 2017-08-11 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |